Martin Höglund
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Martin Höglund has a total of 859 co-authors. Here are the top co-authors by number of shared publications:
- Vladimir Lazarevic
Department of Hematology, Oncology and Radiation Physics, Skåne University Hospital, Lund, Sweden
22 shared publications - Gisela Barbany
Karolinska Institutet
14 shared publications Anna Robelius
Department of Medical Sciences, Hematology, Uppsala University, Uppsala, Sweden
12 shared publications- Linda Fogelstrand
University of Gothenburg
12 shared publications - Lucia Cavelier
Karolinska Institutet
12 shared publications - Martin Jädersten
Center for Hematology and Regenerative Medicine, Karolinska Institutet, Stockholm, Sweden
12 shared publications
Latest Publications
- Open Access
- 8 July 2026
- Published by Springer Nature in Nature
- Vol. 656 (8128) , 752-762
Chromatin landscape and epigenetic heterogeneity of acute myeloid leukaemia
Acute myeloid leukaemia (AML) is an aggressive blood cancer characterized by the unregulated proliferation of immature myeloblasts. Gene mutations have been shown to have a large effect on pathogenesis, inter-tumour heterogeneity and clinical outcomes in AML1,2,3,4,5,6,7,8; however, the role of epigenetic alterations in these respects has been investigated less extensively. Here we use ATAC-seq (assay for transposase-accessible chromatin with sequencing) in a cohort of 1,563 individuals with a recent diagnosis of AML (the ‘eCHROMA’ cohort) to show that AML can be classified into 16 subgroups on the basis of chromatin accessibility profiles. Multiomics analyses of gene mutations, the transcriptome, DNA methylation and histone marks show that these ATAC subgroups exhibit distinct driver mutations, differentiation states, gene expression, DNA methylation and super-enhancer profiles, and are also associated with clinical outcomes. These findings were validated in independent cohorts. Single-cell ATAC sequencing reveals that all leukaemic cells in each subgroup share a common chromatin accessibility profile, which suggests that subgroup-specific epigenomic fingerprints underlie the ATAC-based classification. Mechanistically, the subgroups have distinct gene-regulatory networks that are driven by the activities of key transcription factors in haematopoiesis, and in which subgroup-specific super-enhancers have a pivotal role. Multiomics single-cell analysis further reveals deregulated trajectories of differentiation coupled with chromatin accessibility and gene expression. Notably, ATAC subgroups have an independent prognostic effect, compared with genomic classification, and are associated with particular drug sensitivities. In summary, ATAC-based chromatin profiling, combined with multiomics data, provides insights into AML pathogenesis beyond genomics and constitutes a valuable resource for AML research.
- 8 July 2026
- Published by Springer Nature in Nature
- Vol. 656 (8128) , 752-762
Open AccessChromatin landscape and epigenetic heterogeneity of acute myeloid leukaemia
Acute myeloid leukaemia (AML) is an aggressive blood cancer characterized by the unregulated proliferation of immature myeloblasts. Gene mutations have been shown to have a large effect on pathogenesis, inter-tumour heterogeneity and clinical outcomes in AML1,2,3,4,5,6,7,8; however, the role of epigenetic alterations in these respects has been investigated less extensively. Here we use ATAC-seq (assay for transposase-accessible chromatin with sequencing) in a cohort of 1,563 individuals with a recent diagnosis of AML (the ‘eCHROMA’ cohort) to show that AML can be classified into 16 subgroups on the basis of chromatin accessibility profiles. Multiomics analyses of gene mutations, the transcriptome, DNA methylation and histone marks show that these ATAC subgroups exhibit distinct driver mutations, differentiation states, gene expression, DNA methylation and super-enhancer profiles, and are also associated with clinical outcomes. These findings were validated in independent cohorts. Single-cell ATAC sequencing reveals that all leukaemic cells in each subgroup share a common chromatin accessibility profile, which suggests that subgroup-specific epigenomic fingerprints underlie the ATAC-based classification. Mechanistically, the subgroups have distinct gene-regulatory networks that are driven by the activities of key transcription factors in haematopoiesis, and in which subgroup-specific super-enhancers have a pivotal role. Multiomics single-cell analysis further reveals deregulated trajectories of differentiation coupled with chromatin accessibility and gene expression. Notably, ATAC subgroups have an independent prognostic effect, compared with genomic classification, and are associated with particular drug sensitivities. In summary, ATAC-based chromatin profiling, combined with multiomics data, provides insights into AML pathogenesis beyond genomics and constitutes a valuable resource for AML research.
- Top Cited Papers
- 18 December 2025
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 390 (6779) , eadx2678
A human pan-disease blood atlas of the circulating proteome
The human blood proteome provides a holistic readout of health states through the assessment of thousands of circulating proteins. In this study, we present a pan-disease resource to enable the study of diverse disease phenotypes within a harmonized proteomics dataset. By profiling protein concentrations across 59 diseases and healthy cohorts, we identified proteins associated with age, sex, and body mass index, as well as disease-specific signatures. This study highlights shared and distinct protein patterns across conditions, demonstrating the power of a unified proteomics approach to uncover biological insights. The dataset, covering 8262 individuals and up to 5416 proteins, serves as an online resource for exploring disease-specific protein profiles and advancing precision medicine research.
- 18 December 2025
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 390 (6779) , eadx2678
Top Cited PapersA human pan-disease blood atlas of the circulating proteome
The human blood proteome provides a holistic readout of health states through the assessment of thousands of circulating proteins. In this study, we present a pan-disease resource to enable the study of diverse disease phenotypes within a harmonized proteomics dataset. By profiling protein concentrations across 59 diseases and healthy cohorts, we identified proteins associated with age, sex, and body mass index, as well as disease-specific signatures. This study highlights shared and distinct protein patterns across conditions, demonstrating the power of a unified proteomics approach to uncover biological insights. The dataset, covering 8262 individuals and up to 5416 proteins, serves as an online resource for exploring disease-specific protein profiles and advancing precision medicine research.
- Open Access
- 15 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from Validation of Guidelines for Genetic Investigation of Myeloid Neoplasms with Germline Predisposition: Results from a Prospective Cohort Study
Supplementary Table 1. List of genes assessed by copy number analysis on WES data.
- 15 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from Validation of Guidelines for Genetic Investigation of Myeloid Neoplasms with Germline Predisposition: Results from a Prospective Cohort Study
Supplementary Table 1. List of genes assessed by copy number analysis on WES data.
- Open Access
- 15 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from Validation of Guidelines for Genetic Investigation of Myeloid Neoplasms with Germline Predisposition: Results from a Prospective Cohort Study
Supplementary Figure 2. Diagnostic yield criterion-based when all patients fulfilling CytoMol criterion (n=39) are assigned to CytoMol regardless of whether they were included in the study based on another criteria. MH: medical history; FH: family history; S-FH: strong family history; CytoMol: inclusion due to findings in the somatic profiling; P: Pathogenic; LP: likely pathogenic; VUS: variant of unknown significance.
- 15 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from Validation of Guidelines for Genetic Investigation of Myeloid Neoplasms with Germline Predisposition: Results from a Prospective Cohort Study
Supplementary Figure 2. Diagnostic yield criterion-based when all patients fulfilling CytoMol criterion (n=39) are assigned to CytoMol regardless of whether they were included in the study based on another criteria. MH: medical history; FH: family history; S-FH: strong family history; CytoMol: inclusion due to findings in the somatic profiling; P: Pathogenic; LP: likely pathogenic; VUS: variant of unknown significance.
- Open Access
- 15 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 5 from Validation of Guidelines for Genetic Investigation of Myeloid Neoplasms with Germline Predisposition: Results from a Prospective Cohort Study
Supplementary Figure 5. Overall survival in patients with AML (A) or MDS (B) based on whether a P/LP germline variant in a well-established gene for hereditary blood disorders was found (“Yes”, blue line) or not (“No”, grey line). Comparison among subgroups was performed using the Log-rank test, with the resulting p-value presented within the plot.
- 15 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 5 from Validation of Guidelines for Genetic Investigation of Myeloid Neoplasms with Germline Predisposition: Results from a Prospective Cohort Study
Supplementary Figure 5. Overall survival in patients with AML (A) or MDS (B) based on whether a P/LP germline variant in a well-established gene for hereditary blood disorders was found (“Yes”, blue line) or not (“No”, grey line). Comparison among subgroups was performed using the Log-rank test, with the resulting p-value presented within the plot.
- Open Access
- 15 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from Validation of Guidelines for Genetic Investigation of Myeloid Neoplasms with Germline Predisposition: Results from a Prospective Cohort Study
Supplementary Table 2. List of genes that have been proposed to be associated with HHM during the study time.
- 15 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from Validation of Guidelines for Genetic Investigation of Myeloid Neoplasms with Germline Predisposition: Results from a Prospective Cohort Study
Supplementary Table 2. List of genes that have been proposed to be associated with HHM during the study time.
- Open Access
- 15 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from Validation of Guidelines for Genetic Investigation of Myeloid Neoplasms with Germline Predisposition: Results from a Prospective Cohort Study
Supplementary Figure 3. Pedigrees and Relative telomere length (TL) in two patients with a missense VUS in TERT measured by qPCR in peripheral blood leukocytes as previously described.1 The reference percentiles were determined from telomere length analysis of blood leukocytes from 283 healthy subjects (0–78 years of age). The curves shown depict the first, 10th, 50th, 90th, and 99th normal percentiles at each age, where the 50th percentile represents the mean. A) Patient GH01_P11 was included due to cytopenias, premature graying of hair, infections, skin hypomelanosis. The variant segregated in the mother, who did not show clinical signs of telomere biology disorders but displayed shorter TL. B) Patient GH01_P33 was included due to MDS, lung fibrosis, premature graying of hair. The family history was positive for lung fibrosis on paternal side and for leukemia and premature graying of hair on the maternal side. Segregation analysis in parental samples was not possible. Reference: 1. Norberg A, Rosén A, Raaschou-Jensen K, et al: Novel variants in Nordic patients referred for genetic testing of telomere-related disorders. Eur J Hum Genet 26:858–867, 2018
- 15 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from Validation of Guidelines for Genetic Investigation of Myeloid Neoplasms with Germline Predisposition: Results from a Prospective Cohort Study
Supplementary Figure 3. Pedigrees and Relative telomere length (TL) in two patients with a missense VUS in TERT measured by qPCR in peripheral blood leukocytes as previously described.1 The reference percentiles were determined from telomere length analysis of blood leukocytes from 283 healthy subjects (0–78 years of age). The curves shown depict the first, 10th, 50th, 90th, and 99th normal percentiles at each age, where the 50th percentile represents the mean. A) Patient GH01_P11 was included due to cytopenias, premature graying of hair, infections, skin hypomelanosis. The variant segregated in the mother, who did not show clinical signs of telomere biology disorders but displayed shorter TL. B) Patient GH01_P33 was included due to MDS, lung fibrosis, premature graying of hair. The family history was positive for lung fibrosis on paternal side and for leukemia and premature graying of hair on the maternal side. Segregation analysis in parental samples was not possible. Reference: 1. Norberg A, Rosén A, Raaschou-Jensen K, et al: Novel variants in Nordic patients referred for genetic testing of telomere-related disorders. Eur J Hum Genet 26:858–867, 2018
- Open Access
- 15 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 4 from Validation of Guidelines for Genetic Investigation of Myeloid Neoplasms with Germline Predisposition: Results from a Prospective Cohort Study
Supplementary Table 4. Pairwise Comparisons of Survival Outcomes using cox proportional hazards regression. The figure in main manuscript or supplementary materials showing the Kaplan-Meier analysis for the same comparison is also indicated. * indicates when HR could not be calculated due to lack of events in one of the groups being compared.
- 15 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 4 from Validation of Guidelines for Genetic Investigation of Myeloid Neoplasms with Germline Predisposition: Results from a Prospective Cohort Study
Supplementary Table 4. Pairwise Comparisons of Survival Outcomes using cox proportional hazards regression. The figure in main manuscript or supplementary materials showing the Kaplan-Meier analysis for the same comparison is also indicated. * indicates when HR could not be calculated due to lack of events in one of the groups being compared.
- Open Access
- 15 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 4 from Validation of Guidelines for Genetic Investigation of Myeloid Neoplasms with Germline Predisposition: Results from a Prospective Cohort Study
Supplementary Figure 4. Oncoplot showing the most frequently mutated genes among 62 patients with malignant disease included in the study where results from the diagnostic somatic panel performed during routine workup were available. Although the panel was performed as tumor-only in 53 patients, the data is presented as tumor-normal for all, since confirmed germline variants were not included in the analysis. Each column represents an individual sample, while each row corresponds to a specific gene. The presence of mutations is indicated by colored blocks, where light blue indicates single-hit, while red a multi-hit in the same gene. The barchart to the right of the oncoplot provides a summary count of mutations in specific genes. Patients are sorted according to the affected gene according to results from germline investigations.
- 15 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 4 from Validation of Guidelines for Genetic Investigation of Myeloid Neoplasms with Germline Predisposition: Results from a Prospective Cohort Study
Supplementary Figure 4. Oncoplot showing the most frequently mutated genes among 62 patients with malignant disease included in the study where results from the diagnostic somatic panel performed during routine workup were available. Although the panel was performed as tumor-only in 53 patients, the data is presented as tumor-normal for all, since confirmed germline variants were not included in the analysis. Each column represents an individual sample, while each row corresponds to a specific gene. The presence of mutations is indicated by colored blocks, where light blue indicates single-hit, while red a multi-hit in the same gene. The barchart to the right of the oncoplot provides a summary count of mutations in specific genes. Patients are sorted according to the affected gene according to results from germline investigations.
- Open Access
- 15 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 3 from Validation of Guidelines for Genetic Investigation of Myeloid Neoplasms with Germline Predisposition: Results from a Prospective Cohort Study
Supplementary Table 3. Overview of included patients and genetic findings.HGVS=Human Genome Variation Society.
- 15 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 3 from Validation of Guidelines for Genetic Investigation of Myeloid Neoplasms with Germline Predisposition: Results from a Prospective Cohort Study
Supplementary Table 3. Overview of included patients and genetic findings.HGVS=Human Genome Variation Society.